CN108619159A - 护肤品制剂、其制备方法及其应用 - Google Patents
护肤品制剂、其制备方法及其应用 Download PDFInfo
- Publication number
- CN108619159A CN108619159A CN201810366285.9A CN201810366285A CN108619159A CN 108619159 A CN108619159 A CN 108619159A CN 201810366285 A CN201810366285 A CN 201810366285A CN 108619159 A CN108619159 A CN 108619159A
- Authority
- CN
- China
- Prior art keywords
- parts
- skin care
- care item
- item preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 41
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims abstract description 22
- 229960005091 chloramphenicol Drugs 0.000 claims abstract description 22
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 21
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 21
- 150000002576 ketones Chemical class 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 239000000758 substrate Substances 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 235000013343 vitamin Nutrition 0.000 claims abstract description 15
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 15
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 14
- 206010000496 acne Diseases 0.000 claims abstract description 14
- 231100000241 scar Toxicity 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims description 33
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 240000002547 Rosa roxburghii Species 0.000 claims description 12
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 11
- 229940099259 vaseline Drugs 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 235000012907 honey Nutrition 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 206010053615 Thermal burn Diseases 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 12
- 208000017520 skin disease Diseases 0.000 abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 206010048768 Dermatosis Diseases 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 5
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 5
- 239000003908 antipruritic agent Substances 0.000 abstract description 5
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 20
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229940011671 vitamin b6 Drugs 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 235000019158 vitamin B6 Nutrition 0.000 description 8
- 239000011726 vitamin B6 Substances 0.000 description 8
- 229920001353 Dextrin Polymers 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 244000178870 Lavandula angustifolia Species 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000001102 lavandula vera Substances 0.000 description 4
- 235000018219 lavender Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- HEVGGTGPGPKZHF-UHFFFAOYSA-N 1-(1,2-dimethyl-3-methylidenecyclopentyl)-4-methylbenzene Chemical compound CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000255964 Pieridae Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- IGODOXYLBBXFDW-UHFFFAOYSA-N alpha-Terpinyl acetate Chemical compound CC(=O)OC(C)(C)C1CCC(C)=CC1 IGODOXYLBBXFDW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008151 pyridoxamine Nutrition 0.000 description 2
- 239000011699 pyridoxamine Substances 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241001529749 Lavandula Species 0.000 description 1
- 235000002997 Lavandula Nutrition 0.000 description 1
- 241000219991 Lythraceae Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000490567 Pinctada Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 241001083505 Punica Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002478 diastatic effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- -1 methane series hydrocarbon Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
Abstract
一种护肤品制剂、其制备方法及其应用，涉及皮肤药剂技术领域。该护肤品制剂包括膏剂基质和以下重量份的原料：0.3‑3份磺胺、3‑15份酮康他索、1‑6份氯霉素、0.001‑0.01份地塞米松以及0.1‑0.2份维生素B6。该护肤品制剂具有止痒、消炎、消痘、祛肿、除疤的作用，且可治疗多种皮肤病，其具有起效快、复发率低、无副作用和后遗症的优点。此外本发明还涉及上述护肤品制剂的制备方法及其应用。
Description
技术领域
本发明涉及一种皮肤药剂技术领域，且特别涉及一种护肤品制剂、其制备方法及其应用。
背景技术
皮肤病(dermatosis)是发生在皮肤和皮肤附属器官疾病的总称，皮肤作为人体的第一道生理防线时刻参与着机体的功能活动，维持着人体机体和自然环境的对立统一，人体机体的异常情况也可以在皮肤表面反映出来，当皮肤的生理功能受到损害时，就会引起皮肤病，皮肤病的产生原因和病症也多种多样，目前现有常用的皮肤病药物有很多，一般都是通过皮肤表层涂覆的方法起到消毒、杀菌、镇痛的作用，但这些药物大多是针对某种皮肤病进行治疗，并不能对常见的多种皮肤疾病如青春痘、皮肤瘙痒、皮肤烧伤、皮肤烫伤、皮肤肿胀等疾病均具有较好的疗效，不能满足一药多能的要求。
因此，需要一种能够对多种皮肤病症均具有较好疗效的药物以满足要求。
发明内容
本发明的目的在于提供一种护肤品制剂，具有止痒、消炎、消痘、祛肿、除疤的作用，且可治疗多种皮肤病，其具有起效快、复发率低、无副作用和后遗症的优点。
本发明的另一目的在于提供上述护肤品制剂的制备方法，该制备方法操作简单方法，适合大规模生产。
本发明的另一目的在于提供上述护肤品制剂在制备治疗痤疮、过敏、瘙痒、烧伤、烫伤、激光手术伤疤的药物中的应用。
本发明解决其技术问题是采用以下技术方案来实现的。
本发明提出一种护肤品制剂，其包括膏剂基质和以下重量份的原料：0.3-3份磺胺、3-15份酮康他索、1-6份氯霉素、0.001-0.01份地塞米松以及0.1-0.2份维生素B6。
进一步地，在本发明较佳实施例中，其包括以下重量份的原料：0.4-2.5份磺胺、4-12份酮康他索、2-4份氯霉素、0.003-0.009份地塞米松以及0.1-0.18份维生素B6。
进一步地，在本发明较佳实施例中，其包括以下重量份的原料：0.5-1.5份磺胺、5-10份酮康他索、2-4份氯霉素、0.005-0.009份地塞米松以及0.1-0.15份维生素B6。
进一步地，在本发明较佳实施例中，原料还包括1-3重量份的珍珠粉。
进一步地，在本发明较佳实施例中，膏剂基质包括凡士林、蜂蜜、糊精中的至少一种以及刺梨籽油、薰衣草油、石榴籽油中的至少两种。
进一步地，在本发明较佳实施例中，原料和膏剂基质的质量比为1：1-5。
本发明还提供了一种护肤品制剂的制备方法，其包括以下步骤：以重量份数计，将0.3-3份磺胺、3-15份酮康他索、1-6份氯霉素、0.001-0.01份地塞米松以及0.1-0.2份维生素B6分别粉碎后混匀得到粉料；
将1-5倍粉料质量的膏剂基质溶于水中得到基质；
将粉料加入到基质中搅拌均匀。
进一步地，在本发明较佳实施例中，膏剂基质和水的质量比为1：0.2-0.8。
进一步地，在本发明较佳实施例中，制备粉料时还加入1-3重量份的珍珠粉。
本发明还提供了上述护肤品制剂在制备治疗痤疮、过敏、瘙痒、烧伤、烫伤、激光手术伤疤的药物中的应用。
本发明实施例的护肤品制剂、其制备方法及其应用的有益效果是：护肤品制剂包括膏剂基质和以下重量份的原料：0.3-3份磺胺、3-15份酮康他索、1-6份氯霉素、0.001-0.01份地塞米松以及0.1-0.2份维生素B6。该护肤品制剂采用具有抑菌效果的磺胺、用于治疗真菌感染的酮康他索、具有抗菌能力的氯霉素、具有抗炎抗过敏效果的地塞米松以及具有缓和伤口溃烂和提高免疫力功能的维生素B6配合使用制备得到，具有止痒、消炎、消痘、祛肿、除疤的作用，且可治疗多种皮肤病，起效快、复发率低且具有无副作用和后遗症的优点。本发明还涉及上述护肤品制剂的制备方法，该方法操作简单方便，能够大规模的生产和制备护肤品制剂。此外本发明还公开了上述护肤品制剂在制备治疗痤疮、过敏、瘙痒、烧伤、烫伤、激光手术伤疤的药物中的应用。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚，下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
下面对本发明实施例的护肤品制剂、其制备方法及其应用进行具体说明。
本发明提出一种护肤品制剂，其包括膏剂基质和以下重量份的原料：0.3-3份磺胺、3-15份酮康他索、1-6份氯霉素、0.001-0.01份地塞米松以及0.1-0.2份维生素B6。优选的，护肤品制剂包括以下重量份的原料：0.4-2.5份磺胺、4-12份酮康他索、2-4份氯霉素、0.003-0.009份地塞米松以及0.1-0.18份维生素B6；更优选的，护肤品制剂包括以下重量份的原料：0.5-1.5份磺胺、5-10份酮康他索、2-4份氯霉素、0.005-0.009份地塞米松以及0.1-0.15份维生素B6；进一步优选的，原料还包括1-3重量份的珍珠粉；更进一步优选的，膏剂基质包括凡士林、蜂蜜、糊精中的至少一种以及刺梨籽油、薰衣草油、石榴籽油中的至少两种；再进一步优选的，原料和膏剂基质的质量比为1：1-5。
该护肤品制剂采用具有抑菌效果的磺胺、用于治疗真菌感染的酮康他索、具有抗菌能力的氯霉素、具有抗炎抗过敏效果的地塞米松以及具有缓和伤口溃烂和提高免疫力功能的维生素B6配合起到缓释、保湿、灭菌、消炎作用的膏剂基质制备得到，该护肤品制剂具有止痒、消炎、消痘、祛肿、除疤的作用，且可治疗多种皮肤病，起效快、复发率低且具有无副作用和后遗症的优点。
其中：磺胺(sulfanilamide)别名对氨基苯磺酰胺，分子式：C6H8N2O2S，其是白色颗粒或粉末状结晶，无臭，味微苦，微溶于冷水、乙醇、甲醇、乙醚和丙酮，易溶于沸水、甘油、盐酸、氢氧化钾及氢氧化钠溶液，不溶于氯仿、乙醚、苯、石油醚，磺胺作为药物使用时对细菌的生长繁殖有抑制作用，但是大量服用磺胺会因吸收与排泄失去平衡而致死。
酮康他索为复方制剂，每克酮康他索含酮康唑10mg、丙酸氯倍他索0.25mg，其主要用于治疗皮肤浅表的真菌感染，如手癣、足癣、体癣、股癣等。
氯霉素(chloramphenicol)是白色或无色的针状或片状结晶，熔点149.7-150.79℃，易溶于甲醇、乙醇、丙醇及乙酸乙酯，微溶于乙醚及氯仿，不溶于石油醚及苯。氯霉素为广谱抑菌剂，其通过脂溶性弥散进入细菌细胞内阻止蛋白质合成进行抑菌。
地塞米松(Dexamethasone)是一种人工合成的皮质类固醇，其具有抗炎、抗内毒素、抑制免疫、抗休克及增强应激反应等作用，可用于治疗多种症状，包含风湿性疾病、部分皮肤病、严重过敏、哮喘、炎症等疾病。
维生素B6(Vitamin B6)又称吡哆素，其包括吡哆醇、吡哆醛及吡哆胺，在体内以磷酸酯的形式存在，是一种水溶性维生素。维生素B6为无色晶体，易溶于水及乙醇，在酸液中稳定，在碱液中易破坏，吡哆醇耐热，吡哆醛和吡哆胺不耐高温。维生素B6为人体内某些辅酶的组成成分，参与多种代谢反应，尤其是和氨基酸代谢有密切关系。维生素B6能够提高伤口的愈合速度，且能够提高人体的免疫力。
珍珠(Pernulo)产于珍珠贝类和珠母贝类软体动物体内，其是由内分泌作用而生成的含碳酸钙的矿物珠粒，珍珠药用在中国已有数千年历史，本草纲目中记载珍珠具有美白、除斑的功效，能够有效的去除伤口的疤痕和色斑，其还具有收敛生肌、清热排毒、祛痘、控油、深层清洁皮肤等功效。
凡士林(vaseline)是烷系烃或饱和烃类半液态的混合物，其涂抹在皮肤表面能够形成油膜，使皮肤表面水分不易蒸发散失，保持皮肤的湿润状态并阻挡来自空气中的细菌和皮肤接触，从而降低皮肤感染病菌的可能。
蜂蜜对于细菌具有较强的抑制作用，能够有效的提高灭杀皮肤表面的细菌，避免细菌对皮肤造成感染，此外蜂蜜的保水作用也能够保证皮肤的湿润状态。
糊精是淀粉在加热、酸或淀粉酶作用下发生分解和水解时产生的小分子物质，糊精具有较高的保湿能力和粘结性，并对皮肤进行保护避免细菌和皮肤接触造成感染。
刺梨(Rose Roxburghii Tratt)是蔷薇科蔷薇属多年生落叶丛生灌木，将刺梨籽采用超临界CO2萃取得到刺梨籽油。刺梨籽油的主要成分为40％的亚油酸、25％的亚麻酸、12％的油酸以及其他脂肪酸，刺梨籽油具有调节机体免疫功能、延缓衰老、抗动脉粥样硬化、抗肿瘤等功效。
薰衣草(Lavandula)为唇形科薰衣草属植物，薰衣草油是薰衣草的花序经水蒸气蒸馏得到，薰衣草油为无色至淡黄色液体，其主要成分为乙酸芳樟酯、薰衣草醇、芳樟醇、松油醇、香叶醇、橙花醇、樟脑、龙脑、乙酸松油酯、乙酸薰衣草酯、壬醛、蒎烯、月桂烯、罗勒烯等，其具有清热解毒，祛风止痒的功效。
石榴籽油是由石榴科石榴属浆果石榴(Punica granatum L.)的种籽制取得到的油脂。石榴籽油主要包括石榴酸、亚麻酸、亚油酸、油酸、棕榈酸、硬脂酸等六种脂肪酸，其中石榴酸的含量约占86％，使石榴籽油具有抗氧化、抗炎症的功效，能够有效的提高对皮肤的保护并灭杀皮肤表面的细菌，避免皮肤感染。
本发明还提供了一种护肤品制剂的制备方法，其包括以下步骤：以重量份数计，将0.3-3份磺胺、3-15份酮康他索、1-6份氯霉素、0.001-0.01份地塞米松以及0.1-0.2份维生素B6分别粉碎后混匀得到粉料；优选的，制备粉料时还加入1-3重量份的珍珠粉。
将1-5倍粉料质量的膏剂基质溶于水中得到基质；优选的，膏剂基质和水的质量比为1：0.2-0.8。
将粉料加入到基质中搅拌均匀。
本发明实施例提供的护肤品制剂的制备方法是将主要原料粉碎后混合均匀得到粉料，并将膏剂基质溶于水制成胶体后与粉料混合均匀得到，能够有效的保留原料中的各组分的灭菌、消炎、清热、护肤成分，该制备方法操作简单方便，能够大规模的工艺生产制备护肤品制剂。
本发明还提供了上述护肤品制剂在制备治疗痤疮、过敏、瘙痒、烧伤、烫伤、激光手术伤疤的药物中的应用，采用该护肤品制剂作为原料制备的药物能够有效的缓解和治疗上述的病症，且具有用量少，疗效好的优点。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
本发明实施例提供了一种护肤品制剂，其是由以下步骤制备得到：
将12g磺胺、60g酮康他索、50g氯霉素、0.01g地塞米松以及1.5g维生素B6分别粉碎后混匀得到粉料。
将80g凡士林、25g刺梨籽油和25g薰衣草油溶于60g水中得到基质。
将粉料加入到基质中搅拌均匀。
实施例2
本发明实施例提供了一种护肤品制剂，其是由以下步骤制备得到：
将10g磺胺、50g酮康他索、30g氯霉素、0.03g地塞米松以及1.2g维生素B6分别粉碎后混匀得到粉料。
将40g凡士林、40g蜂蜜、20g石榴籽油和25g薰衣草油溶于60g水中得到基质。
将粉料加入到基质中搅拌均匀。
实施例3
本发明实施例提供了一种护肤品制剂，其是由以下步骤制备得到：
将25g磺胺、90g酮康他索、40g氯霉素、0.08g地塞米松、20g珍珠粉以及1g维生素B6分别粉碎后混匀得到粉料。
将60g凡士林、60g蜂蜜、60g糊精、30g刺梨籽油、30g薰衣草油和30g石榴籽油溶于200g水中得到基质。
将粉料加入到基质中搅拌均匀。
实施例4
本发明实施例提供了一种护肤品制剂，其是由以下步骤制备得到：
将30g磺胺、120g酮康他索、55g氯霉素、0.1g地塞米松以及2g维生素B6分别粉碎后混匀得到粉料。
将100g凡士林、50g蜂蜜、50g糊精、50g刺梨籽油、50g薰衣草油和50g石榴籽油溶于200g水中得到基质。
将粉料加入到基质中搅拌均匀。
实施例5
本发明实施例提供了一种护肤品制剂，其是由以下步骤制备得到：
将6g磺胺、50g酮康他索、20g氯霉素、0.06g地塞米松以及1g维生素B6分别粉碎后混匀得到粉料。
将30g凡士林、30g糊精、15g刺梨籽油和15g薰衣草油溶于60g水中得到基质。
将粉料加入到基质中搅拌均匀。
实施例6
本发明实施例提供了一种护肤品制剂，其是由以下步骤制备得到：
将9g磺胺、55g酮康他索、25g氯霉素、0.08g地塞米松以及1.2g维生素B6分别粉碎后混匀得到粉料。
将40g凡士林、20g蜂蜜、20g糊精、10g刺梨籽油、10g石榴籽油和10g薰衣草油溶于55g水中得到基质。
将粉料加入到基质中搅拌均匀。
对比例1
采用阿达帕林基质作为对比例。
采用上述实施例1、实施例2、实施例3、实施例4、实施例5和实施例6制备得到的护肤品制剂和对比例1、对比例2进行临床实验。
将本发明实施例提供的护肤品制剂送重庆市计量质量检测研究院检测，结果如下：汞(mg/kg)<0.006(规定限值1)；铝mg/kg<5(规定限值10)；砷mg/kg<0.04(规定限值2)，全部检测结果均合格。
选取28位15-30岁的患痘者，并随机选取15名患痘者分成三组分别使用上述实施例1、实施例2、实施例3制备得到的护肤品制剂，每天使用两次，每次用量0.5-1g，使用3天后15位患者均明显感觉脸部炎症消退，使用7天后15位患者均出现脸部皮脂分泌减少，皮损改善，使用15-20天15位患者中的13位脸部老化死皮去除，仅3位患者仍具有少量丘疹。安排剩余的13名患痘者使用对比例1提供的阿达帕林凝胶，使用后15天仅4名患者感觉脸部炎症有所缓解，使用30天后仅7名患者感觉脸部炎症有所消退。
选取13名身体烧伤患者分别使用上述实施例4、实施例5、实施例6制备得到的护肤品制剂，使用5天后13名患者均感觉烧伤部位痒痛感减弱，使用20天后13名患者中的11位的伤处愈合程度明显改善，使用35天后13名患者的伤处部分疤痕明显消除。
综上所述，本发明实施例提供的护肤品制剂具有止痒、消炎、消痘、祛肿、除疤的作用，且可治疗多种皮肤病，起效快、复发率低且具有无副作用和后遗症的优点。本发明提供的上述护肤品制剂的制备方法操作简单方便，能够大规模的生产和制备护肤品制剂。本发明还公开了上述护肤品制剂在制备治疗痤疮、过敏、瘙痒、烧伤、烫伤、激光手术伤疤的药物中的应用。
以上所描述的实施例是本发明一部分实施例，而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围，而是仅仅表示本发明的选定实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
Claims (10)
1.一种护肤品制剂，其特征在于，其包括膏剂基质和以下重量份的原料：
2.根据权利要求1所述的护肤品制剂，其特征在于，其包括以下重量份的原料：
3.根据权利要求1所述的护肤品制剂，其特征在于，其包括以下重量份的原料：
4.根据权利要求1所述的护肤品制剂，其特征在于，所述原料还包括1-3重量份的珍珠粉。
5.根据权利要求1所述的护肤品制剂，其特征在于，所述膏剂基质包括凡士林、蜂蜜、糊精中的至少一种以及刺梨籽油、薰衣草油、石榴籽油中的至少两种。
6.根据权利要求5所述的护肤品制剂，其特征在于，所述原料和所述膏剂基质的质量比为1：1-5。
7.一种护肤品制剂的制备方法，其特征在于，其包括以下步骤：以重量份数计，将0.3-3份磺胺、3-15份酮康他索、1-6份氯霉素、0.001-0.01份地塞米松以及0.1-0.2份维生素B6分别粉碎后混匀得到粉料；
将1-5倍所述粉料质量的膏剂基质溶于水中得到基质；
将所述粉料加入到所述基质中搅拌均匀。
8.根据权利要求7所述的护肤品制剂的制备方法，其特征在于，所述膏剂基质和所述水的质量比为1：0.2-0.8。
9.根据权利要求7所述的护肤品制剂的制备方法，其特征在于，制备所述粉料时还加入1-3重量份的珍珠粉。
10.根据权利要求1-6中任一项所述的护肤品制剂在制备治疗痤疮、过敏、瘙痒、烧伤、烫伤、激光手术伤疤的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810366285.9A CN108619159A (zh) | 2018-04-23 | 2018-04-23 | 护肤品制剂、其制备方法及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810366285.9A CN108619159A (zh) | 2018-04-23 | 2018-04-23 | 护肤品制剂、其制备方法及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108619159A true CN108619159A (zh) | 2018-10-09 |
Family
ID=63694354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810366285.9A Pending CN108619159A (zh) | 2018-04-23 | 2018-04-23 | 护肤品制剂、其制备方法及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108619159A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791093A (zh) * | 2021-02-09 | 2021-05-14 | 淄博美联臣美容医院有限公司 | 治疗痤疮的透皮给药组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803069A (en) * | 1985-06-18 | 1989-02-07 | Biogal Gyogyszergyar | Composition for the treatment of acne |
| CN1130065A (zh) * | 1995-10-23 | 1996-09-04 | 滇虹天然药物厂 | 复方酮康唑外用制剂 |
| CN104127422A (zh) * | 2014-07-17 | 2014-11-05 | 李泽填 | 一种治疗瘙痒和青春痘的组合物及其制备方法 |
-
2018
- 2018-04-23 CN CN201810366285.9A patent/CN108619159A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803069A (en) * | 1985-06-18 | 1989-02-07 | Biogal Gyogyszergyar | Composition for the treatment of acne |
| CN1130065A (zh) * | 1995-10-23 | 1996-09-04 | 滇虹天然药物厂 | 复方酮康唑外用制剂 |
| CN104127422A (zh) * | 2014-07-17 | 2014-11-05 | 李泽填 | 一种治疗瘙痒和青春痘的组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 王海燕: "《实用药物学应用指南》", 30 September 2009, 中医古籍出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791093A (zh) * | 2021-02-09 | 2021-05-14 | 淄博美联臣美容医院有限公司 | 治疗痤疮的透皮给药组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5694665B2 (ja) | 局所製剤とその用法 | |
| JP6064156B2 (ja) | 深部体温上昇剤 | |
| WO2008140200A1 (en) | External compositions for the skin | |
| US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
| WO2016141219A1 (en) | Strontium based compositions and formulations for pain, pruritus, and inflammation | |
| WO2013000382A1 (zh) | 脂肪酸组合物和植物提取物与药物制剂及其应用 | |
| US20190343907A1 (en) | Synergistic Compositions and Methods of Achieving Homeostasis in Mammalian Systems | |
| WO2012090194A2 (en) | Compositions and methods for treating a skin disorder | |
| US20220233627A1 (en) | Compositions comprising plant extracts and oils and related methods of treatment and their preparation | |
| IE60403B1 (en) | Pharmaceutical use of graminaceous extracts | |
| CN104983844A (zh) | 具有粘膜修复功能的组合物配方及其制剂的制备过程 | |
| JP2003212786A (ja) | 竹の抽出成分を有効成分とする皮膚外用薬 | |
| CN110150664A (zh) | 一种改善痤疮的玫瑰花功能食品 | |
| CN108619159A (zh) | 护肤品制剂、其制备方法及其应用 | |
| CN101433544B (zh) | 具有抗炎消肿镇痛作用的外用药物组合物制剂与用途 | |
| KR20090091547A (ko) | 항염 및 피부자극완화용 화장료 조성물 | |
| US11298393B2 (en) | Composition comprising a mixture of an extract and bentonite | |
| KR20100089409A (ko) | 여드름 개선용 화장료 조성물 | |
| JP4716497B2 (ja) | 皮膚外用剤およびヒアルロニダーゼ阻害剤 | |
| KR20130033228A (ko) | 화장료 및 피부질환 치료용 조성물 | |
| JP7153429B2 (ja) | 活性酸素消去剤 | |
| BRPI0706837A2 (pt) | uso de compostos epoxidados | |
| CN110038031A (zh) | 一种油性抑菌膏及其制备方法 | |
| Shafi | GREEN BLOOD THERAPY IN MODERN MEDICINE. | |
| EP4240385A1 (en) | Radiation-induced fibrosis treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |
|
| RJ01 | Rejection of invention patent application after publication |